Skip to content

Serotonin: all studies

Page 277 of 401: studies 2,761 to 2,770 of 4,004, newest first. Back to the serotonin overview

Research

Evaluation of Sensorimotor Gating Deficits in Mice Through Prepulse Inhibition (PPI) of the Startle Response.

Methods in molecular biology (Clifton, N.J.) 2023 Paula Unzueta-Larrinaga, Leyre Urigüen 1 citation

Prepulse inhibition of the startle response enables measuring animal behavior and helps us understand core aspects of neuropsychiatric diseases. Prepulse inhibition is considered a translational indicator of sensorimotor gating deficits present in schizophrenia patients and is crucial in the characterization of animal models of schizophrenia-like behaviors. Hallucinogenic drugs acting through...

DOI: 10.1007/978-1-0716-3307-6_5 (opens in new tab) Full text (opens in new tab) Animal models Doi Prepulse inhibition Psychiatric disorders +5

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial.

Frontiers in Psychiatry 2023 Ellen James, David Erritzøe, Tiffanie Benway et al. 16 citations

Due to their potential impact on mood and wellbeing there has been increasing interest in the potential of serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) in the treatment of major depressive disorder (MDD). The aim of Part A of this study was to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) profile of escalating doses of SPL026 (DMT fumarate)...

Effects of Ketanserin, M100907 and Olanzapine on hallucinogenic like action induced by 2,5-dimethoxy-4-methylamphetamine

Behavioural Pharmacology December 27, 2022 Kaixi Li, Xiao-Yan Liu, Mei Zhang et al.

2,5-dimethoxy-4-methylamphetamine (DOM) is a kind of hallucinogen of phenylalkylamine. Psychedelic effects mainly include audiovisual synesthesia, complex imagery, disembodiment etc. that can impair control and cognition leading to adverse consequences such as suicide. By now, there are no specific drugs regarding the management of classic hallucinogen use clinically. We evaluated the effects...

A unified model of ketamine's dissociative and psychedelic properties.

Journal of Psychopharmacology December 17, 2022 Miriam Marguilho, Inês Figueiredo, Pedro Castro-Rodrigues 57 citations

Ketamine is an N-methyl-d-aspartate antagonist which is increasingly being researched and used as a treatment for depression. In low doses, it can cause a transitory modification in consciousness which was classically labelled as ‘dissociation’. However, ketamine is also commonly classified as an atypical psychedelic and it has been recently reported that ego dissolution experiences during...

DOI: 10.1177/02698811221140011 (opens in new tab) Full text (opens in new tab) Psychopharmacology Mental health Consciousness research Ketamine therapy

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology

Neurosurgery December 8, 2022 Akanksha Sharma, Shanthi Gowrinathan, Karina Sergi et al. 13 citations

After a decades-long pause, psychedelics are again being intensely investigated for treating a wide range of neuropsychiatric ailments including depression, anxiety, addiction, post-traumatic stress disorder, anorexia, and chronic pain syndromes. The classic serotonergic psychedelics psilocybin and lysergic acid diethylamide and nonclassic psychedelics 3,4-methylenedioxymethamphetamine and...

Toward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans

Biological Psychiatry December 7, 2022 Flora Moujaes, Katrin H. Preller, Jie Lisa Ji et al. 44 citations

Precision psychiatry aims to identify markers of interindividual variability that allow for predicting the right treatment for each patient. However, bridging the gap between molecular-level manipulations and neural systems-level functional alterations remains an unsolved problem in psychiatry. After decades of low success rates in pharmaceutical research and development for psychiatric drugs,...

A PLANTA AYAHUASCA NO TRATAMENTO DA DEPRESSÃO

Revista interdisciplinar em saúde December 7, 2022 Mariana Beatriz Gomes de Abreu, Yuri Oliveira Barreto, Pedro José Targino Ribeiro et al.

Introdução: A depressão é um transtorno mental com grande chance de ser a principal causa de incapacidade e desgaste mental em âmbito mundial até a previsão máxima em 2030 e estima-se que cerca de 5,8% da população brasileira já seja acometida pela mesma. Uma vez que a Depressão acarreta uma série de efeitos nocivos ao ser humano, como baixa autoestima, por exemplo, a intervenção farmacológica...

Use of the head-twitch response to investigate the structure–activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines

Psychopharmacology December 7, 2022 Adam L. Halberstadt, Dino Luethi, Marius C. Hoener et al. 7 citations

Abstract Rationale 4-Thio-substituted phenylalkylamines such as 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2) and 2,5-dimethoxy-4- n -propylthiophenethylamine (2C-T-7) produce psychedelic effects in humans and have been distributed as recreational drugs. Objectives The present studies were conducted to examine the structure–activity relationships (SAR) of a series of 4-thio-substituted...

Altered states, alkaloids, and catatonia: Monoaminoxidase inhibitors and their role in the history of psychopharmacology.

Frontiers in Pharmacology December 6, 2022

Monoamine oxidases are mitochondrial enzymes that catalyze the oxidative deamination of biogenic amines (adrenaline, noradrenaline, serotonin, and dopamine), causing their inactivation and subsequently playing a fundamental role in the homeostasis of various neurotransmitters. As the regulation of these effects was deemed important in clinical practice, numerous modulators of these enzymes were...

Ecstasy metabolites and monoamine neurotransmitters upshift the Na+/K+ ATPase activity in mouse brain synaptosomes.

Archives of Toxicology December 2022 Daniel José Barbosa, João Paulo Capela, Luísa Maria Ferreira et al.

3,4-Methylenedioximethamphetamine (MDMA; "ecstasy") is a psychotropic drug with well-known neurotoxic effects mediated by hitherto not fully understood mechanisms. The Na+- and K+-activated adenosine 5'-triphosphatase (Na+/K+ ATPase), by maintaining the ion gradient across the cell membrane, regulates neuronal excitability. Thus, a perturbation of its function strongly impacts cell homeostasis,...

DOI: 10.1007/s00204-022-03370-7 (opens in new tab) Full text (opens in new tab) 3,4-Methylenedioxymethamphetamine MDMA MDMA Brain Effects MDMA Metabolites Monoamine neurotransmitters +2